
MRK-560
CAS No. 677772-84-8
MRK-560 ( —— )
产品货号. M26763 CAS No. 677772-84-8
MRK-560 是一种有效的脑渗透性 γ-分泌酶抑制剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥1037 | 有现货 |
![]() ![]() |
10MG | ¥1596 | 有现货 |
![]() ![]() |
25MG | ¥3216 | 有现货 |
![]() ![]() |
50MG | ¥5014 | 有现货 |
![]() ![]() |
100MG | ¥7152 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称MRK-560
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述MRK-560 是一种有效的脑渗透性 γ-分泌酶抑制剂。
-
产品描述MRK-560 is an effective and brain-penetrant inhibitor of γ-secretase.
-
体外实验MRK-560 (30, 100, 300, 1000 nM; 15days) blocks mutant NOTCH1 receptor signaling in human T-ALL cell lines.Cell Proliferation Assay Cell Line:HPB-ALL, DND-41, and Jurkat cells Concentration:30, 100, 300, 1000 nM Incubation Time:15 days Result:Reduced NICD1 generation in cells and resulted in a dose-dependent decrease of proliferation in HPB-ALL and DND-41, which depend on NOTCH signaling for their survival.
-
体内实验MRK-560 (15.54 mg/kg; S.C.; single daily for 14 days) shows strong antileukemic effects on T-ALL model.MRK-560 (1, 3, 10, 30, 100 mg/kg; p.o.; single) shows good blood-brain barrier permeability in a dose-dependent manner in rats.MRK-560 (1, 3, 10, 30, 100 mg/kg; p.o.; single) inhibits the production of Aβ levels in brain and cerebrospinal fluid.MRK-560 (1 mg/kg; p.o.; single) shows a good bioavailability of 70 to 90%, and Tmax is 12 h.MRK-560 (1 mg/kg; i.v.; single) is suitable for once-a-day dosing (with a low plasma clearance and a half-life of more than 15 h). Animal Model:Tg (HLA-DRB1) 31Dmz/Szj (NSG) mice (T-ALL (T cell acute lymphoblastic leukemia) model).Dosage:15.54 mg/kg Administration:Subcutaneous injection; single daily for 14 days. Result:Resulted in strong antileukemic effects and improved median survival to 30 days compared to 18 days in vehicle-treated mice.Animal Model:Male Sprague-Dawley rats (250-300 g).Dosage:1, 3, 10, 30, 100 mg/kg Administration:Oral administration; single (experiment is performed 8 h later)Result:Increased the plasma and brain concentrations in a dose-dependent manner.Reduced (dose-dependent) both brain and CSF Aβ levels, with essentially complete inhibition of the production of both peptides being observed at a dose of 100 mg/kg.Animal Model:Male Sprague-Dawley rats (250-300 g).Dosage:1 mg/kg Administration:Intravenously and orally administration; single.Result:Showed Tmax after the oral dose was 12 h,and bioavailability was 70 to 90%.Revealed a low plasma clearance of less than 5 mL/min/kg with a volume of distribution of approximately 6 L/kg, which translated to a long half-life of more than 15 h.
-
同义词——
-
通路Neuroscience
-
靶点Gamma-secretase
-
受体KEAP1-Nrf2
-
研究领域——
-
适应症——
化学信息
-
CAS Number677772-84-8
-
分子量517.91
-
分子式C19H17ClF5NO4S2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (193.08 mM)
-
SMILESFc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Richard Steel, et al. Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction. ACS Med Chem Lett. 2012 May 10;3(5):407-410.
产品手册




关联产品
-
Aβ-IN-1
Aβ-IN-1 is a novel, potent and orally active γ-secretase modulator (GSM). Aβ-IN-1 potently reduced Aβ42 levels with an IC 50 value of 0.091 μM in cultured cells without inhibiting CYP3A4. Aβ-IN-1 shows a sustained pharmacokinetic profile.
-
CB-103
CB-103是一种口服活性的Notch信号通路抑制剂,具有抗肿瘤活性。 CB-103 在人 T 细胞急性淋巴细胞白血病癌细胞系中表现出阻断 NOTCH 信号传导的能力,并在 GSI 耐药 T-ALL 细胞系中表现出抗肿瘤功效。
-
NVP-TNKS656
NVP-TNKS656 是一种高效、选择性、口服活性的 TNKS2 抑制剂。